Attached files
| file | filename |
|---|---|
| EX-10.38 - UNANIMOUS SHAREHOLDERS' AGREEMENT - Pivot Pharmaceuticals Inc. | pvotf_ex1038.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 19, 2018
| PIVOT PHARMACEUTICALS INC. | ||||
| (Exact name of registrant as specified in its charter) |
| British Columbia |
| 333-161157 |
| n/a |
| (State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| 1275 West 6th Avenue, Vancouver, British Columbia, Canada |
| V6H 1A6 | |||
| (Address of principal executive offices) |
| (Zip Code) | |||
Registrant’s telephone number, including area code (604) 805-7783
n/a
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
On December 17, 2018, we entered into a Unanimous Shareholders’ Agreement with Cartagena Leaf Inc., a subsidiary of Mexico-based Licorera Del Sur, to create a joint venture corporation. The joint venture corporation will develop and commercialize cannabis-infused non-alcoholic beverages combining the expertise of Licorera del Sur with our patented Solumer™ and RTIC™ powderization technologies.
Item 9.01 Financial Statements and Exhibits
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| PIVOT PHARMACEUTICALS INC. |
| |
|
|
|
|
|
| Date: December 19, 2018 | By: | /s/ Patrick Frankham |
|
|
|
| Patrick Frankham |
|
|
|
| Chief Executive Officer |
|
| 3 |